Human Health Biotechnologies to 2015:
This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cel...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch Artikel |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2010
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions. |
| Beschreibung: | 1 Online-Ressource (95 p.) 19 x 27cm. |
| DOI: | 10.1787/gen_papers-2009-5kmjkjtfxdg7 |
Internformat
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-061267899 | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210204s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/gen_papers-2009-5kmjkjtfxdg7 |2 doi | |
| 035 | |a (DE-627-1)061267899 | ||
| 035 | |a (DE-599)KEP061267899 | ||
| 035 | |a (FR-PaOEC)gen_papers-2009-5kmjkjtfxdg7 | ||
| 035 | |a (EBP)061267899 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arundel, Anthony |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Human Health Biotechnologies to 2015 |c Anthony, Arundel, David, Sawaya and Ioana, Valeanu |
| 264 | 1 | |a Paris |b OECD Publishing |c 2010 | |
| 300 | |a 1 Online-Ressource (95 p.) |c 19 x 27cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions. | ||
| 650 | 4 | |a Economics | |
| 700 | 1 | |a Sawaya, David |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Valeanu, Ioana |e MitwirkendeR |4 ctb | |
| 773 | 0 | 8 | |i Enthalten in |t OECD Journal: General Papers |g Vol. 2009, no. 3, p. 113-207 |
| 773 | 1 | 8 | |g volume:2009 |g year:2009 |g number:3 |g pages:113-207 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 912 | |a ZDB-13-SOC-article | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a AR | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-061267899 |
|---|---|
| _version_ | 1816797353778085888 |
| adam_text | |
| any_adam_object | |
| author | Arundel, Anthony |
| author2 | Sawaya, David Valeanu, Ioana |
| author2_role | ctb ctb |
| author2_variant | d s ds i v iv |
| author_facet | Arundel, Anthony Sawaya, David Valeanu, Ioana |
| author_role | aut |
| author_sort | Arundel, Anthony |
| author_variant | a a aa |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC ZDB-13-SOC-article |
| ctrlnum | (DE-627-1)061267899 (DE-599)KEP061267899 (FR-PaOEC)gen_papers-2009-5kmjkjtfxdg7 (EBP)061267899 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/gen_papers-2009-5kmjkjtfxdg7 |
| format | Electronic Article |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02965caa a22003852 4500</leader><controlfield tag="001">ZDB-13-SOC-061267899</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121342.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210204s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)061267899</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP061267899</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)gen_papers-2009-5kmjkjtfxdg7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)061267899</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Arundel, Anthony</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Human Health Biotechnologies to 2015</subfield><subfield code="c">Anthony, Arundel, David, Sawaya and Ioana, Valeanu</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (95 p.)</subfield><subfield code="c">19 x 27cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economics</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sawaya, David</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valeanu, Ioana</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">OECD Journal: General Papers</subfield><subfield code="g">Vol. 2009, no. 3, p. 113-207</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2009</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:113-207</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC-article</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-061267899 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-26T14:56:14Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (95 p.) 19 x 27cm. |
| psigel | ZDB-13-SOC ZDB-13-SOC-article |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | OECD Publishing |
| record_format | marc |
| spelling | Arundel, Anthony VerfasserIn aut Human Health Biotechnologies to 2015 Anthony, Arundel, David, Sawaya and Ioana, Valeanu Paris OECD Publishing 2010 1 Online-Ressource (95 p.) 19 x 27cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions. Economics Sawaya, David MitwirkendeR ctb Valeanu, Ioana MitwirkendeR ctb Enthalten in OECD Journal: General Papers Vol. 2009, no. 3, p. 113-207 volume:2009 year:2009 number:3 pages:113-207 FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 Volltext |
| spellingShingle | Arundel, Anthony Human Health Biotechnologies to 2015 Economics |
| title | Human Health Biotechnologies to 2015 |
| title_auth | Human Health Biotechnologies to 2015 |
| title_exact_search | Human Health Biotechnologies to 2015 |
| title_full | Human Health Biotechnologies to 2015 Anthony, Arundel, David, Sawaya and Ioana, Valeanu |
| title_fullStr | Human Health Biotechnologies to 2015 Anthony, Arundel, David, Sawaya and Ioana, Valeanu |
| title_full_unstemmed | Human Health Biotechnologies to 2015 Anthony, Arundel, David, Sawaya and Ioana, Valeanu |
| title_short | Human Health Biotechnologies to 2015 |
| title_sort | human health biotechnologies to 2015 |
| topic | Economics |
| topic_facet | Economics |
| url | https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |
| work_keys_str_mv | AT arundelanthony humanhealthbiotechnologiesto2015 AT sawayadavid humanhealthbiotechnologiesto2015 AT valeanuioana humanhealthbiotechnologiesto2015 |